MedTrace Logo

Treatment Study of Bipolar Depression

NCT00947791 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-05-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether a single intravenous administration of an N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar depression.

Conditions

Interventions

DRUG

ketamine

a single IV infusion of ketamine, IV 0.5 mg/kg

DRUG

midazolam

a single IV infusion of midazolam, 0.045 mg/kg

Sponsors & Collaborators

Principal Investigators

  • James W Murrough, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-10-31
Completion
2009-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947791 on ClinicalTrials.gov